IMRX
Immuneering Corporation$4.77-0.09 (-1.85%)Prev Close$4.86·MCap$202.4M·P/E—·Vol493.6K·Yield—
▲
Buys (12M)
23
$919.9K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$919.9K
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Immuneering Corporation (IMRX) has been exclusively buying, with 23 insider purchases totaling $919.9K and 0 insider sales totaling $0.00. The most recent insider transaction was by Schall Thomas J. (director), who purchased $101.0K worth of shares on Jan 20, 2026. Immuneering Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $202.4M.
IMRX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Schall Thomas J. | director | Buy | 21,645 | $4.67 | $101.0K | 74,530 |
| Jan 16, 2026 | Brakewood Harold Eugene | Chief Business Officer | Buy | 5,250 | $4.76 | $25.0K | 0 |
| Jan 15, 2026 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,298 | $4.57 | $10.5K | 0 |
| Jan 15, 2026 | Neufeld Leah R | officer: CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 25,970 |
| Jan 15, 2026 | Schall Thomas J. | Director | Buy | 21,645 | $4.67 | $101.0K | 0 |
| Jan 14, 2026 | Feinberg Peter | director | Buy | 20,000 | $4.35 | $86.9K | 135,441 |
| Jan 13, 2026 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 0 |
| Jan 12, 2026 | Feinberg Peter | Director | Buy | 20,000 | $4.35 | $86.9K | 0 |
| Oct 3, 2025 | Feinberg Peter | Director | Buy | 7,500 | $6.67 | $50.0K | 0 |
| Oct 1, 2025 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | Buy | 1,020 | $6.83 | $7.0K | 0 |
| Oct 1, 2025 | Morales Mallory | Chief Accounting Officer | Buy | 300 | $6.39 | $1.9K | 0 |
| Oct 1, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 800 | $6.38 | $5.1K | 0 |
| Sep 30, 2025 | Feinberg Peter | Director | Buy | 7,500 | $7.03 | $52.7K | 0 |
| Sep 29, 2025 | Feinberg Peter | Director | Buy | 5,000 | $7.18 | $35.9K | 0 |
| Jul 2, 2025 | HAUSMAN DIANA | Director | Buy | 5,500 | $3.61 | $19.9K | 0 |
| Jul 2, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 700 | $3.57 | $2.5K | 0 |
| Jul 1, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 10,000 | $3.49 | $34.9K | 0 |
| Jun 27, 2025 | Schall Thomas J. | Director | Buy | 9,500 | $3.66 | $34.8K | 0 |
| Jun 20, 2025 | Brakewood Harold Eugene | Chief Business Officer | Buy | 1,900 | $2.53 | $4.8K | 0 |
| Jun 20, 2025 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 13,422 | $2.58 | $34.6K | 0 |
| Jun 18, 2025 | Feinberg Peter | Director | Buy | 25,000 | $2.53 | $63.2K | 0 |
| Jun 18, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 21,000 | $2.39 | $50.1K | 0 |
| Jun 17, 2025 | Schall Thomas J. | Director | Buy | 40,485 | $2.21 | $89.3K | 0 |
| Apr 3, 2024 | Cormorant Asset Management, LP | Sell | 400,000 | $2.90 | $1.16M | 3,295,173 | |
| Mar 25, 2024 | Brakewood Harold Eugene | Chief Business Officer | Buy | 3,900 | $2.57 | $10.0K | 3,900 |
| Mar 25, 2024 | Feinberg Peter | Director | Buy | 25,000 | $2.55 | $63.7K | 111,766 |
| Mar 25, 2024 | Morales Mallory | Chief Accounting Officer | Buy | 1,500 | $2.67 | $4.0K | 8,278 |
| Mar 25, 2024 | Schall Thomas J. | Buy | 2,900 | $2.55 | $7.4K | 2,900 | |
| Mar 21, 2024 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 7,000 | $2.86 | $20.0K | 345,896 |
| Mar 21, 2024 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 3,818 | $2.88 | $11.0K | 10,029 |
| Mar 19, 2024 | BERMAN ANN E | Director | Buy | 57,965 | $2.13 | $123.4K | 67,465 |
| Mar 19, 2024 | Feinberg Peter | Director | Buy | 75,000 | $2.44 | $183.1K | 86,766 |
| Mar 19, 2024 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 20,000 | $2.77 | $55.3K | 2,281,852 |
| Mar 18, 2024 | Cormorant Asset Management, LP | Sell | 909,091 | $3.02 | $2.75M | 3,859,098 | |
| May 27, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,551 | $3.92 | $10.0K | 332,685 |
| May 18, 2022 | Bookman Michael | GENERAL COUNSEL AND SECRETARY | Buy | 1,000 | $4.88 | $4.9K | 2,402 |
| May 17, 2022 | KEATING LAURIE | Buy | 7,000 | $5.00 | $35.0K | 14,000 | |
| May 12, 2022 | Amin Biren | CFO, TREASURER | Buy | 1,000 | $4.42 | $4.4K | 7,898 |
| Mar 24, 2022 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 3,000 | $8.02 | $24.1K | 2,257,352 |
| Mar 23, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 1,050 | $7.91 | $8.3K | 330,134 |
| Mar 22, 2022 | Barrett Scott | CHIEF MEDICAL OFFICER | Buy | 900 | $7.49 | $6.7K | 7,563 |
| Mar 16, 2022 | Feinberg Peter | Buy | 6,667 | $6.75 | $45.0K | 11,766 | |
| Mar 15, 2022 | BERMAN ANN E | Buy | 6,000 | $6.40 | $38.4K | 9,500 | |
| Sep 21, 2021 | Feinberg Peter | Buy | 4,750 | $24.45 | $116.1K | 5,099 | |
| Sep 15, 2021 | Feinberg Peter | Buy | 6,099 | $21.50 | $131.1K | 392,242 | |
| Sep 14, 2021 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 2,083 | $22.87 | $47.6K | 2,602,352 |
| Aug 5, 2021 | Cormorant Asset Management, LP | Buy | 550,000 | $15.00 | $8.25M | 2,252,628 | |
| Aug 4, 2021 | Amin Biren | CFO, Treasurer | Buy | 4,175 | $15.00 | $62.6K | 6,898 |
| Aug 4, 2021 | Barrett Scott | Chief Medical Officer | Buy | 667 | $15.00 | $10.0K | 6,663 |
| Aug 4, 2021 | BERMAN ANN E | Director | Buy | 3,500 | $15.00 | $52.5K | 3,500 |
Showing 1–50 of 56
1 / 2
IMRX Insider Buying Activity
The following table shows recent insider purchases of Immuneering Corporation (IMRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Schall Thomas J. | director | Buy | 21,645 | $4.67 | $101.0K | 74,530 |
| Jan 16, 2026 | Brakewood Harold Eugene | Chief Business Officer | Buy | 5,250 | $4.76 | $25.0K | 0 |
| Jan 15, 2026 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,298 | $4.57 | $10.5K | 0 |
| Jan 15, 2026 | Neufeld Leah R | officer: CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 25,970 |
| Jan 15, 2026 | Schall Thomas J. | Director | Buy | 21,645 | $4.67 | $101.0K | 0 |
| Jan 14, 2026 | Feinberg Peter | director | Buy | 20,000 | $4.35 | $86.9K | 135,441 |
| Jan 13, 2026 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 0 |
| Jan 12, 2026 | Feinberg Peter | Director | Buy | 20,000 | $4.35 | $86.9K | 0 |
| Oct 3, 2025 | Feinberg Peter | Director | Buy | 7,500 | $6.67 | $50.0K | 0 |
| Oct 1, 2025 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | Buy | 1,020 | $6.83 | $7.0K | 0 |
| Oct 1, 2025 | Morales Mallory | Chief Accounting Officer | Buy | 300 | $6.39 | $1.9K | 0 |
| Oct 1, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 800 | $6.38 | $5.1K | 0 |
| Sep 30, 2025 | Feinberg Peter | Director | Buy | 7,500 | $7.03 | $52.7K | 0 |
| Sep 29, 2025 | Feinberg Peter | Director | Buy | 5,000 | $7.18 | $35.9K | 0 |
| Jul 2, 2025 | HAUSMAN DIANA | Director | Buy | 5,500 | $3.61 | $19.9K | 0 |
| Jul 2, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 700 | $3.57 | $2.5K | 0 |
| Jul 1, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 10,000 | $3.49 | $34.9K | 0 |
| Jun 27, 2025 | Schall Thomas J. | Director | Buy | 9,500 | $3.66 | $34.8K | 0 |
| Jun 20, 2025 | Brakewood Harold Eugene | Chief Business Officer | Buy | 1,900 | $2.53 | $4.8K | 0 |
| Jun 20, 2025 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 13,422 | $2.58 | $34.6K | 0 |
| Jun 18, 2025 | Feinberg Peter | Director | Buy | 25,000 | $2.53 | $63.2K | 0 |
| Jun 18, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 21,000 | $2.39 | $50.1K | 0 |
| Jun 17, 2025 | Schall Thomas J. | Director | Buy | 40,485 | $2.21 | $89.3K | 0 |
| Mar 25, 2024 | Brakewood Harold Eugene | Chief Business Officer | Buy | 3,900 | $2.57 | $10.0K | 3,900 |
| Mar 25, 2024 | Feinberg Peter | Director | Buy | 25,000 | $2.55 | $63.7K | 111,766 |
| Mar 25, 2024 | Morales Mallory | Chief Accounting Officer | Buy | 1,500 | $2.67 | $4.0K | 8,278 |
| Mar 25, 2024 | Schall Thomas J. | Buy | 2,900 | $2.55 | $7.4K | 2,900 | |
| Mar 21, 2024 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 7,000 | $2.86 | $20.0K | 345,896 |
| Mar 21, 2024 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 3,818 | $2.88 | $11.0K | 10,029 |
| Mar 19, 2024 | BERMAN ANN E | Director | Buy | 57,965 | $2.13 | $123.4K | 67,465 |
| Mar 19, 2024 | Feinberg Peter | Director | Buy | 75,000 | $2.44 | $183.1K | 86,766 |
| Mar 19, 2024 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 20,000 | $2.77 | $55.3K | 2,281,852 |
| May 27, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,551 | $3.92 | $10.0K | 332,685 |
| May 18, 2022 | Bookman Michael | GENERAL COUNSEL AND SECRETARY | Buy | 1,000 | $4.88 | $4.9K | 2,402 |
| May 17, 2022 | KEATING LAURIE | Buy | 7,000 | $5.00 | $35.0K | 14,000 | |
| May 12, 2022 | Amin Biren | CFO, TREASURER | Buy | 1,000 | $4.42 | $4.4K | 7,898 |
| Mar 24, 2022 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 3,000 | $8.02 | $24.1K | 2,257,352 |
| Mar 23, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 1,050 | $7.91 | $8.3K | 330,134 |
| Mar 22, 2022 | Barrett Scott | CHIEF MEDICAL OFFICER | Buy | 900 | $7.49 | $6.7K | 7,563 |
| Mar 16, 2022 | Feinberg Peter | Buy | 6,667 | $6.75 | $45.0K | 11,766 | |
| Mar 15, 2022 | BERMAN ANN E | Buy | 6,000 | $6.40 | $38.4K | 9,500 | |
| Sep 21, 2021 | Feinberg Peter | Buy | 4,750 | $24.45 | $116.1K | 5,099 | |
| Sep 15, 2021 | Feinberg Peter | Buy | 6,099 | $21.50 | $131.1K | 392,242 | |
| Sep 14, 2021 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 2,083 | $22.87 | $47.6K | 2,602,352 |
| Aug 5, 2021 | Cormorant Asset Management, LP | Buy | 550,000 | $15.00 | $8.25M | 2,252,628 | |
| Aug 4, 2021 | Amin Biren | CFO, Treasurer | Buy | 4,175 | $15.00 | $62.6K | 6,898 |
| Aug 4, 2021 | Barrett Scott | Chief Medical Officer | Buy | 667 | $15.00 | $10.0K | 6,663 |
| Aug 4, 2021 | BERMAN ANN E | Director | Buy | 3,500 | $15.00 | $52.5K | 3,500 |
IMRX Insider Selling Activity
The following table shows recent insider sales of Immuneering Corporation (IMRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Cormorant Asset Management, LP | Sell | 400,000 | $2.90 | $1.16M | 3,295,173 | |
| Mar 18, 2024 | Cormorant Asset Management, LP | Sell | 909,091 | $3.02 | $2.75M | 3,859,098 |
IMRX Insiders
Similar Stocks to IMRX
VRTX
Vertex Pharmaceuticals Incorporated
$455.37-0.57%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$734.60-0.45%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$314.37+1.04%
$42.07B
INSM
Insmed Incorporated
$138.49-3.82%
$30.07B
UTHR
United Therapeutics Corporation
$524.88-0.39%
$23.50B
MRNA
Moderna, Inc.
$51.11-2.43%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.30-1.82%
$20.08B
RPRX
Royalty Pharma plc
$45.49-0.11%
$19.56B